To The Moon

💰 Winning in chaos requires strong fundamentals!

💹 $Amgen(AMGN)$/$AbbVie(ABBV)$/$Johnson & Johnson(JNJ)$: Here are the outperformers, who also offer astonishing dividend yields.

📣 Stay tuned and supercharge purchasing power with CashBoost!

America is back!

In a prominent position on the White House official website, a carefully designed portrait of President Trump occupies the core area of the homepage, and the bold font "AMERICA IS BACK" creates a strong visual impact.

On March 4, President Trump began his speech to the joint session of Congress with "America is back!" During the speech, the venue presented a clear bipartisan divide. Republicans frequently applauded enthusiastically, while most Democrats had no reaction. Some lawmakers even shouted that Trump's remarks were "lies one after another" when he talked about his achievements.

On March 3, US President Trump said that the US's 25% tariff on Mexican and Canadian goods will take effect on March 4. But just 1-2 days later, he said that he might reach a compromise with Canada and Mexico.

He always seems to like to mess everything up and then rebuild a new order. But in essence, he is a businessman, and in fact, he also follows the usual thinking of businessmen-first ask for a very high price, and then compromise.

Appendix 1 of Trump's autobiography "Never Give Up" "Trump's Law of Success" Article 1: "You must set extremely high goals - this will force the other party to redefine what is 'reasonable'.

Whatever，the current US stock market is full of uncertainty and volatility. If you want to win in chaos, strong fundamentals are essential. Since 2025, the Healthcare sector has continued to be popular in the market. In addition to short-term speculation targets such as HIMS and TEMS, stocks that bring both profit and interest in Healthcare Industry are also worth paying attention to!

Stocks that bring both profit and interest in Healthcare Industry

A giant leading biotech innovation: Amgen (AMGN)

Company Profile

$Amgen(AMGN)$ is a leading global biopharmaceutical company that focuses on the research and development and commercialization of innovative therapies, especially in oncology, cardiovascular disease and inflammation. Its blockbuster drugs such as Prolia, an osteoporosis treatment, and Kyprolis, an anticancer drug, continue to contribute stable cash flow. In recent years, the company has accelerated the layout of gene therapy and AI-driven drug development to further consolidate its technological moat.

Recent stock price performance

AMGN's stock performance has been relatively stable. After several corrections, the stock price has remained steadily upward and has a stable dividend record. The dividend yield is 3.05%, with a year-to-date increase of 21.46%, and the dividend has increased for 13 consecutive years.

Highlights

• AMGN cooperates with a number of technology companies to apply AI algorithms to gene sequencing and protein structure prediction, significantly improving the success rate of drug development. The company has launched AI-assisted diagnostic tools for high-incidence diseases such as diabetes and obesity, and provides personalized treatment plans based on patient data.

It should be noted that the weight loss effect of its weight loss drug MariTide in the second phase of the trial last year did not meet expectations, and there is a risk of drug development failure.

The charm of steady growth and high dividends: AbbVie (ABBV)

Company Profile

$AbbVie(ABBV)$ focuses on innovative drugs and biologics, and owns star products such as Humira. The company has leading technologies in multiple therapeutic areas such as immunology and oncology, and its product portfolio is diverse and constantly innovative.

Recent stock price performance

ABBV has shown strong defensiveness in market fluctuations, and its stock price has risen steadily. At the same time, the company adheres to a high dividend strategy and continues to provide investors with generous returns. The dividend yield is 3.1%, with a year-to-date increase of 19.04%, and the number of consecutive years of dividend growth is 52.

Highlights

• Known for the global "drug king" Humira, despite facing competition from biosimilars, its immunology pipeline successor products Skyrizi and Rinvoq have rapidly increased in volume.

• Benefiting from the global trend of medical digitalization, ABBV is accelerating the promotion of AI-assisted diagnosis and treatment solutions in the Asian and European markets.

With mature product lines and high dividends, ABBV not only provides investors with stable return expectations in the healthcare sector, but also has high growth potential. It is an ideal choice for seeking defensive configurations in the current market turmoil.

Steady defender : Johnson & Johnson (JNJ)

Company Profile

$Johnson & Johnson(JNJ)$ is one of the world's largest integrated healthcare companies, with businesses covering pharmaceuticals, healthcare devices and consumer health products. The company's diversified product portfolio and global sales network enable it to maintain a stable performance in various market environments.

Recent stock price performance

JNJ has demonstrated strong resistance to declines and steady growth with its stable fundamentals and consistent high dividend strategy, maintaining a positive trend for several consecutive trading days. The dividend yield is 3%, and the year-to-date increase is 14.18%. The dividend growth has continued for 62 years, the longest record of the S&P 500.

Highlights

• Diversified business layout brings JNJ a stable source of income, sustained healthy cash flow and steady profit performance, providing strong support for its dividend policy.

• The global market network and deep brand influence enable JNJ to maintain a high market share and competitiveness in the face of economic uncertainty.

As a comprehensive giant in the healthcare industry, JNJ not only has stable operating performance, but its consistent shareholder return policy and low volatility also provide solid protection for long-term investors. It is an excellent target for pursuing stable returns and risk hedging.

Summary

Against the background of Trump's strong political declaration of "America is back!" , in the current market environment full of uncertainty, stocks with solid fundamentals and a balance of growth and dividends undoubtedly provide investors with a steady path. The risk ranking is: AMGN＞ABBV＞JNJ

• $Amgen(AMGN)$ : Relying on leading biotech innovation and diversified product portfolio, it has both growth and stable dividends. However, Humira's revenue decline and pipeline dependence are still the main risks.

• $AbbVie(ABBV)$: With star products and active strategic integration, it continues to give back to shareholders while growing steadily.

• $Johnson & Johnson(JNJ)$: With diversified business and global layout, it has become the most defensive healthcare giant in the market.

Stay tuned. Comment, like and subscribe to @Tiger_Contra

A tool to boost your purchasing power and trading ideas with CashBoost!

Open a CBA today and enjoy access to a trading limit of up to SGD 20,000 with upcoming 0-commission, unlimited trading on SG, HK, and US stocks, as well as ETFs. Find out more here.

Other helpful links:

• 💰Join the TB Contra Telegram Group to Get $10 Trading Vouchers Now🎉

• How to open a CBA.

• How to link your CDP account.

• Other FAQs on CBA.

• Cash Boost Account Website.